ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

MedImmune, Advaxis Test Combo Therapy

by Rick Mullin
July 28, 2014 | APPEARED IN VOLUME 92, ISSUE 30

AstraZeneca’s MedImmune unit will collaborate with Advaxis, a U.S.-based specialist in developing cancer immunotherapies. The pair plans Phase I and II trials that combine MedImmune’s MEDI4736, an anti-PD-L1 immune checkpoint inhibitor, with Advaxis’s ADXS-HPV vaccine as a treatment for patients with certain cervical, head, and neck cancers associated with human papillomavirus. Advaxis will fund and conduct the study. MedImmune has first right of negotiation for further development of combinations involving MEDI4736 and ADXS-HPV.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment